Prescient announces results of SPP & Launches Placement
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Prescient Therapeutics announces the results of its Share Purchase Plan and the launch of a follow-on placement for investors. Additionally, Prescient has entered a trading halt to facilitate the placement at the same share price as the SPP.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- Trading Halt
- Prescient Therapeutics - Extension of Share Purchase Plan
- PTX Opens First U.S. Site for PTX-100 Phase 2a Trial
- Prescient Therapeutics Extends Share Purchase Plan
- Prescient Therapeutics Opens Share Purchase Plan
Later from Prescient Therapeutics
- June 2025 Quarterly Update and Appendix 4C
- Prescient successfully completes $3 million Placement
- Appendix 4E and 2025 Annual Report
- September Quarterly Updated and Appendix 4C
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics